Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
Acquiring Company
Bristol Myers Squibb
Acquired Company
Mirador Therapeutics
PrincetonSan DiegoManufacturingBiotechnologyProfessional ServicesHealth CareMedicalTherapeuticsPharmaceuticalLegalBiopharmaLaw EnforcementBiotechnologyDescription
Bristol Myers Squibb has successfully completed the acquisition of Mirati Therapeutics, Inc., further diversifying and strengthening its oncology portfolio. Through this acquisition, Bristol Myers Squibb has added the commercialized lung cancer medicine KRAZATI to its portfolio, as well as several promising clinical assets, reinforcing its commitment to delivering innovative treatments for cancer patients.
Other recent acquisitions in Professional Services and Medical
Deals where the buyer or target shares a sector with this one, within 45 days, from Fundz verified event records.
- Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform (February 26, 2024)
- XOMA Enters into Agreement to Acquire Kinnate Biopharma for Between $2.3352 and $2.5879 in Cash Per Share Plus a Contingent Value Right (February 16, 2024)
- Lilly Completes Acquisition Of Point Biopharma (December 27, 2023)
- Medline Industries, LP completes acquisition of AG Cuffill® from Hospitech Respiration Ltd. (March 7, 2024)
- PruittHealth Medical Supply completes acquisition of Allied Health Resources (March 6, 2024)
- Branded Legacy, Inc. signs letter of intent to purchase Sycamore BioPharma, LLC, to strengthen its position in the BioTech industry (March 1, 2024)
Who to call at Bristol Myers Squibb, and when
When Bristol Myers Squibb changes hands, the new owners review vendors, systems and leadership. That is when the door opens.
- An alert the day Bristol Myers Squibb raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Bristol Myers Squibb, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Bristol Myers Squibb. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Bristol Myers Squibb makes an acquisition, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Frequently asked
Who acquired Mirador Therapeutics?
Mirador Therapeutics was acquired by Bristol Myers Squibb, based in Princeton. The deal was reported on January 23, 2024. Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Bristol Myers Squibb is publicly traded (BMY) and operates in Manufacturing.
When did Bristol Myers Squibb acquire Mirador Therapeutics?
Bristol Myers Squibb's acquisition of Mirador Therapeutics was reported on January 23, 2024. Bristol Myers Squibb has successfully completed the acquisition of Mirati Therapeutics, Inc., further diversifying and strengthening its oncology portfolio. Fundz records the date the transaction was first publicly reported, sourced from filings and company announcements.
What does Mirador Therapeutics do?
Mirador is a next-generation precision medicine company focused on immunology and inflammation. It is privately held, operating in Biotechnology, and is based in San Diego.
This company was part of an acquisition. Fundz tracks who bought whom, and who to call on both sides.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.